{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:09:23Z","timestamp":1789427363724,"version":"build-2803163510"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Visceral leishmaniasis (VL), a vector-borne disease, is caused by an obligate intramacrophage, kinetoplastid protozoan parasite of the genus <jats:italic>Leishmania<\/jats:italic>. Globally, VL is construed of diversity and complexity concerned with high fatality in tropics, subtropics, and Mediterranean regions with ~50,000\u201390,000 new cases annually. Factors such as the unavailability of licensed vaccine(s), insubstantial measures to control vectors, and unrestrained surge of drug-resistant parasites and HIV-VL co-infections lead to difficulty in VL treatment and control. Furthermore, VL treatment, which encompasses several problems including limited efficacy, emanation of drug-resistant parasites, exorbitant therapy, and exigency of hospitalization until the completion of treatment, further exacerbates disease severity. Therefore, there is an urgent need for the development of safe and efficacious therapies to control and eliminate this devastating disease. In such a scenario, biotherapy\/immunotherapy against VL can become an alternative strategy with limited side effects and no or nominal chance of drug resistance. An extensive understanding of pathogenesis and immunological events that ensue during VL infection is vital for the development of immunotherapeutic strategies against VL. Immunotherapy alone or in combination with standard anti-leishmanial chemotherapeutic agents (immunochemotherapy) has shown better therapeutic outcomes in preclinical studies. This review extensively addresses VL treatment with an emphasis on immunotherapy or immunochemotherapeutic strategies to improve therapeutic outcomes as an alternative to conventional chemotherapy.<\/jats:p>","DOI":"10.3389\/fmed.2023.1096458","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:14:35Z","timestamp":1684300475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunotherapy and immunochemotherapy in combating visceral leishmaniasis"],"prefix":"10.3389","volume":"10","author":[{"given":"Ganesh","family":"Yadagiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakriti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Lal","family":"Mudavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-981-13-1577-0_5","article-title":"Chemotherapy and experimental models of visceral leishmaniasis","author":"Yadagiri","year":"2018","journal-title":"Infect Dis Your Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE."},{"key":"B3","unstructured":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-ento-120811-153557","article-title":"Biology of phlebotomine sand flies as vectors of disease agents","volume":"58","author":"Ready","year":"2013","journal-title":"Annu Rev Entomol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0004386","DOI":"10.1371\/journal.pntd.0004386","article-title":"Concerted efforts to control or eliminate neglected tropical diseases: how much health will be gained?","volume":"2","author":"de Vlas","year":"2016","journal-title":"PLoS Negl. Trop. Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1003053","DOI":"10.1371\/journal.ppat.1003053","article-title":"Determinants for the development of visceral leishmaniasis disease","volume":"9","author":"McCall","year":"2013","journal-title":"PLoS Pathogens"},{"key":"B7","doi-asserted-by":"publisher","first-page":"109956","DOI":"10.1016\/j.mehy.2020.109956","article-title":"Enkephalins as a therapeutic intervention for visceral leishmaniasis","volume":"144","author":"Yadagiri","year":"2020","journal-title":"Med Hypotheses."},{"key":"B8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"van Griensven","year":"2012","journal-title":"Infect Dis Clin North Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00296","article-title":"Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects","volume":"5","author":"Singh","year":"2014","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2013\/675846","article-title":"The burden of visceral leishmaniasis in India: challenges in using remote sensing and GIS to understand and control","volume":"2013","author":"Bhunia","year":"2013","journal-title":"ISRN Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect Dis Poverty."},{"key":"B12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","article-title":"Leishmaniasis\u2014current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft","year":"2003","journal-title":"Trends Parasitol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fimmu.2017.01779","article-title":"Alternative to chemotherapy-the Unmet demand against leishmaniasis","author":"Didwania","year":"2017","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"18","author":"Zijlstra","year":"2003","journal-title":"BMC Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/646932","article-title":"Strategies to overcome antileishmanial drugs unresponsiveness","author":"Sundar","year":"2014"},{"key":"B16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-777X.62883","article-title":"Treatment of visceral leishmaniasis","volume":"2","author":"Moore","year":"2010","journal-title":"J Glob Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/j.1469-0691.2011.03610.x","article-title":"Visceral leishmaniasis: Immunology and prospects for a vaccine","volume":"17","author":"Kaye","year":"2011","journal-title":"Clin Microbiol Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2019.00030","article-title":"Understanding resistance vs. susceptibility in visceral leishmaniasis using mouse models of Leishmania infantumInfection","volume":"9","author":"P\u00e9rez-Cabezas","year":"2019","journal-title":"Front Cell Infect Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2217\/fmb.14.43","article-title":"Immunity to visceral leishmaniasis: implications for immunotherapy","volume":"9","author":"Khadem","year":"2014","journal-title":"Fut Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-016-1553-y","article-title":"Possibilities and challenges for developing a successful vaccine for leishmaniasis","volume":"9","author":"Srivastava","year":"2016","journal-title":"Parasites Vectors."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2914","DOI":"10.1371\/journal.pntd.0002914","article-title":"Immune regulation during chronic visceral leishmaniasis","volume":"8","author":"Faleiro","year":"2014","journal-title":"PLoS Neglect Tropical Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasites Vectors."},{"key":"B23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1590\/0037-8682-0022-2012","article-title":"Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis","volume":"46","author":"Bhattacharya","year":"2013","journal-title":"Rev Soc Bras Med Trop."},{"key":"B24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/bmb\/ldl003","article-title":"Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment","author":"Roberts","year":"2005","journal-title":"Br Med Bull."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/S0036-46652014000100001","article-title":"Animal models for the study of leishmaniasis immunology","volume":"56","author":"Loria-Cervera","year":"2014","journal-title":"Rev Inst Med Trop."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2013.00156","article-title":"Interferon gamma in leishmaniasis","volume":"4","author":"Kima","year":"2013","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00272","article-title":"Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease","volume":"5","author":"Roatt","year":"2014","journal-title":"Front Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1590\/S0034-8910.2014048005615","article-title":"Visceral leishmaniasis in Brazil: rationale and concerns related to reservoir control","volume":"48","author":"Werneck","year":"2014","journal-title":"Rev Saude Publica."},{"key":"B29","first-page":"22","year":"2010","journal-title":"Control of the Leishmaniases"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent antimonials: new perspectives for old drugs","volume":"14","author":"Frezard","year":"2009","journal-title":"Molecules."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1645\/GE-3347","article-title":"Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents","volume":"90","author":"Walker","year":"2004","journal-title":"J Parasitol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An update on pharmacotherapy for leishmaniasis","volume":"16","author":"Sundar","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/2229-5070.129142","article-title":"Drug resistance in leishmaniasis : newer developments","volume":"4","author":"Mohapatra","year":"2014","journal-title":"Trop Parasitol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1086\/520665","article-title":"Amphotericin B treatment for indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions","volume":"45","author":"Sundar","year":"2007","journal-title":"Clin Infect Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.bbrc.2010.07.099","article-title":"Amphotericin B inhibits entry of Leishmania donovani into primary macrophages","volume":"399","author":"Paila","year":"2010","journal-title":"Biochem Biophys Res Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0974-777X.62886","article-title":"Liposomal amphotericin B and leishmaniasis: dose and response","volume":"2","author":"Sundar","year":"2010","journal-title":"J Glob Infect Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-69276-5","article-title":"Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin : an effective oral combination against experimental murine visceral leishmaniasis","volume":"10","author":"Parvez","year":"2020","journal-title":"Sci Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"111279","DOI":"10.1016\/j.msec.2020.111279","article-title":"Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate","volume":"117","author":"Singh","year":"2020","journal-title":"Mater Sci Eng C."},{"key":"B39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"Balasegaram","year":"2012","journal-title":"Expert Opin Emerg Drugs."},{"key":"B40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2165\/00003495-198733030-00002","article-title":"Pentamidine isethionate: a review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia","volume":"33","author":"Goa","year":"1987","journal-title":"Drugs."},{"key":"B41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.7326\/0003-4819-103-5-782","article-title":"Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases","volume":"103","author":"Pearson","year":"1985","journal-title":"Ann Intern Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004087","article-title":"Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study","volume":"9","author":"Diro","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6828","DOI":"10.1128\/AAC.01129-16","article-title":"Antileishmanial mechanism of diamidines involves targeting kinetoplasts","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1378\/chest.110.1.136","article-title":"The safety of IV pentamidine administered in an ambulatory setting","volume":"110","author":"Yeung","year":"1996","journal-title":"Chest."},{"key":"B45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S30139","article-title":"Interest in paromomycin for the treatment of visceral leishmaniasis (Kala-azar)","volume":"8","author":"Wiwanitkit","year":"2012","journal-title":"Ther Clin Risk Manag."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2020.570573","article-title":"Recuperating biopharmaceutical aspects of amphotericin B and paromomycin using a chitosan functionalized nanocarrier via oral route for enhanced anti-leishmanial activity","volume":"10","author":"Parvez","year":"2020","journal-title":"Front Cell Infect Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"104946","DOI":"10.1016\/j.chemphyslip.2020.104946","article-title":"Improvising anti-leishmanial activity of amphotericin B and paromomycin using co-delivery in D-\u03b1-tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored nano-lipid carrier system","volume":"231","author":"Parvez","year":"2020","journal-title":"Chem Phys Lipids."},{"key":"B48","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1086\/605438","article-title":"Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs","volume":"49","author":"Sundar","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.heares.2011.05.008","article-title":"New developments in aminoglycoside therapy and ototoxicity","volume":"281","author":"Xie","year":"2011","journal-title":"Hear Res."},{"key":"B50","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther Clin Risk Manag."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01614-17","article-title":"Mechanism of action of miltefosine on Leishmania donovani involves the impairment of acidocalcisome function and the activation of the sphingosine-dependent plasma membrane Ca 2+ channel","volume":"62","author":"Pinto-Martinez","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/cid\/civ004","article-title":"Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations","volume":"60","author":"Monge-Maillo","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1128\/AAC.00520-11","article-title":"The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase","volume":"55","author":"Carvalho","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/jac\/dkq371","article-title":"Mechanism of interaction of sitamaquine with Leishmania donovani","volume":"65","author":"Coimbra","year":"2010"},{"key":"B55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1051\/parasite\/2011182115","article-title":"Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance","volume":"18","author":"Loiseau","year":"2011","journal-title":"Parasite."},{"key":"B56","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/0974-777X.62863","article-title":"A current perspective on leishmaniasis","volume":"2","author":"Clem","year":"2010","journal-title":"J Glob Infect Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2012.00251","article-title":"Immunobiology of visceral leishmaniasis","volume":"3","author":"Kumar","year":"2012","journal-title":"Front Immunol."},{"key":"B58","first-page":"75","article-title":"The role of toll-like receptor agonists in the immunotherapy of leishmaniosis. An update and proposal for a new form of anti-leishmanial therapy","volume":"60","author":"Dasgupta","year":"2014","journal-title":"Ann Parasitol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: complexity at the host\u2014pathogen interface","volume":"9","author":"Scott","year":"2020","journal-title":"Nat Rev Microbiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/HIV.S143929","article-title":"Visceral leishmaniasis and HIV coinfection: current perspectives","volume":"10","author":"Lindoso","year":"2018","journal-title":"HIV\/AIDS Res Palliat Care."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3389\/fimmu.2018.02529","article-title":"Macrophage polarization in leishmaniasis: broadening horizons","volume":"9","author":"Tomiotto-Pellissier","year":"2018","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms8081201","article-title":"Leishmania immunity: advancing immunotherapy and vaccine development","volume":"8","author":"Ikeogu","year":"2020","journal-title":"Microorganisms."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.4269\/ajtmh.20-0531","article-title":"Targeting IL-27 and\/or IL-10 in experimental murine visceral leishmaniasis","volume":"103","author":"Murray","year":"2020","journal-title":"Am J Trop Med Hyg."},{"key":"B64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00281-020-00788-y","article-title":"Leishmaniasis immunopathology\u2014impact on design and use of vaccines, diagnostics and drugs","volume":"42","author":"Kaye","year":"2020","journal-title":"Semin Immunopathol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/eji.200635937","article-title":"Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells","volume":"36","author":"St\u00e4ger","year":"2006","journal-title":"Eur J Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0134698","DOI":"10.1371\/journal.pone.0134698","article-title":"IL-22 protects against tissue damage during cutaneous leishmaniasis","volume":"10","author":"Gimblet","year":"2015","journal-title":"PLoS ONE."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/516526","article-title":"Response to interferon-\u03b3 plus pentavalent antimony in Indian visceral leishmaniasis","volume":"176","author":"Sundar","year":"1997","journal-title":"J Infect Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/314929","article-title":"Synergistic effect of interferon-\u03b3 and mannosylated liposome- incorporated doxorubicin in the therapy of experimental visceral leishmaniasis","volume":"180","author":"Kole","year":"1999","journal-title":"J Infect Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol."},{"key":"B70","first-page":"197","article-title":"Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS","volume":"12","author":"Mastroianni","year":"2004","journal-title":"Infez med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF01973598","article-title":"Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral leishmaniasis","volume":"13","author":"Badaro","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1128\/AAC.47.8.2513-2517.2003","article-title":"Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis","volume":"47","author":"Murray","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8845826","article-title":"A Chimera of Th1 stimulatory proteins of leishmania donovani offers moderate immunotherapeutic efficacy with a Th1-inclined immune response against visceral leishmaniasis","author":"Ratnapriya","year":"2021","journal-title":"Biomed Res. Int"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-019-3858-0","article-title":"In vitro and in vivo immunomodulatory properties of octyl-\u03b2-d-galactofuranoside during Leishmania donovani infection","volume":"12","author":"Guegan","year":"2019","journal-title":"Parasites Vectors."},{"key":"B75","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.actatropica.2011.05.017","article-title":"Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator\u2014Picroliv","volume":"119","author":"Shakya","year":"2011","journal-title":"Acta Trop."},{"key":"B76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S0031182021001906","article-title":"Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model","volume":"149","author":"Carvalho","year":"2022","journal-title":"Parasitology."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00436-022-07628-y","article-title":"A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model","volume":"121","author":"de Santana","year":"2022","journal-title":"Parasitol Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15406\/moji.2016.04.00121","article-title":"Cytokines and their role in health and disease: A brief overview","volume":"4","author":"Gulati","year":"2016","journal-title":"MOJ Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01265","article-title":"Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update","volume":"10","author":"Lotfi","year":"2019","journal-title":"Front Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know","volume":"16","author":"Shi","year":"2006","journal-title":"Cell Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/S0021-9258(18)71855-3","article-title":"Purification and properties of colony-stimulating factor from mouse lung-conditioned medium","volume":"252","author":"Burgess","year":"1977","journal-title":"J Biol Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1172\/JCI117767","article-title":"Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis","volume":"95","author":"Murray","year":"1995","journal-title":"J Clin Invest."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1084\/jem.166.5.1436","article-title":"Recombinant human granulocyte\/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages","volume":"166","author":"Weiser","year":"1987","journal-title":"J Exp Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1515\/bmc-2018-0007","article-title":"Interferon-gamma (IFN-\u03b3): Exploring its implications in infectious diseases","volume":"9","author":"Kak","year":"2018","journal-title":"Biomol Concepts."},{"key":"B85","first-page":"345","article-title":"Visceral leishmaniasis\u2014current therapeutic modalities","volume":"123","author":"Sundar","year":"2006","journal-title":"Indian J Med Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e3198","DOI":"10.1371\/journal.pntd.0003198","article-title":"Leishmania specific CD4 T cells release IFN-gamma that limits parasite replication in patients with visceral leishmaniasis","volume":"8","author":"Kumar","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/infdis\/171.4.992","article-title":"Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis","volume":"171","author":"Sundar","year":"1995","journal-title":"J Infect Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/1573395054065115","article-title":"Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression","volume":"1","author":"Liu","year":"2005","journal-title":"Curr Immunol Rev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/ijms11030789","article-title":"Interleukin 12 a key immunoregulatory cytokine in infection applications","volume":"11","author":"Hamza","year":"2010","journal-title":"Int J Mol Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.4049\/jimmunol.154.9.4623","article-title":"IL-12 enhances Th1-type responses in human Leishmania donovani infections","volume":"154","author":"Ghalib","year":"1995","journal-title":"J Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.181.1.387","article-title":"Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis","volume":"181","author":"Murray","year":"1995","journal-title":"J Exp Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1086\/315890","article-title":"Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis","volume":"182","author":"Murray","year":"2000","journal-title":"J Infect Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.vaccine.2005.11.058","article-title":"Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis","volume":"24","author":"Tewary","year":"2006","journal-title":"Vaccine."},{"key":"B94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2018.00455","article-title":"Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses","author":"Sch\u00fclke","year":"2018","journal-title":"Front Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"27158","DOI":"10.1074\/jbc.M115.682708","article-title":"Interleukin 10 (IL-10)-mediated Immunosuppression March-i induction regulates antigen presentation by macrophages but not Dendritic cells","volume":"290","author":"Mittal","year":"2015","journal-title":"J Biol Chem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1128\/IAI.69.3.1499-1507.2001","article-title":"Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events","volume":"69","author":"Bhattacharyya","year":"2001","journal-title":"Infect Immun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2019.00670","article-title":"Cytokines: Key determinants of resistance or disease progression in visceral leishmaniasis: opportunities for novel diagnostics and immunotherapy","volume":"10","author":"Dayakar","year":"2019","journal-title":"Front Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/infdis\/jir461","article-title":"IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis","volume":"204","author":"Gautam","year":"2011","journal-title":"J Infect Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1086\/376510","article-title":"Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis","volume":"188","author":"Murray","year":"2003","journal-title":"J Infect Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.03176","article-title":"Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy","volume":"10","author":"Patente","year":"2019","journal-title":"Front Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00078","article-title":"Dendritic cell-based approaches in the fight against diseases","volume":"5","author":"Freitas-Silva","year":"2014","journal-title":"Front. Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1084\/jem.20052288","article-title":"Uptake of Leishmania major by dendritic cells is mediated by Fc\u03b3 receptors and facilitates acquisition of protective immunity","volume":"203","author":"Woelbing","year":"2006","journal-title":"J Exp Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/79734","article-title":"Dendritic cell regulation of TH1-TH2 development","volume":"1","author":"Moser","year":"2000","journal-title":"Nat Immunol."},{"key":"B104","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N","article-title":"Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection","volume":"28","author":"Gorak","year":"1998","journal-title":"Eur J Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.4049\/jimmunol.172.2.1186","article-title":"The dendritic cell receptor DC-SIGN discriminates among species and life cycle forms of leishmania","volume":"172","author":"Colmenares","year":"2004","journal-title":"J Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1016\/j.vaccine.2012.05.075","article-title":"Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis","volume":"30","author":"Agallou","year":"2012","journal-title":"Vaccine."},{"key":"B107","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.4049\/jimmunol.170.11.5625","article-title":"Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis","volume":"170","author":"Ghosh","year":"2003","journal-title":"J Immunol."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.84711","article-title":"\u201cTLR signaling on protozoan and helminthic parasite infection,\u201d in Toll-like Receptors","author":"Fouzder","year":"2020"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1128\/IAI.01388-10","article-title":"Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis","volume":"79","author":"Gallego","year":"2011","journal-title":"Infect Immun."},{"key":"B110","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4049\/jimmunol.1002175","article-title":"Leishmania inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages","volume":"186","author":"Faria","year":"2011","journal-title":"J Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.intimp.2012.02.002","article-title":"Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9","volume":"12","author":"Mukherjee","year":"2012","journal-title":"Int Immunopharmacol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1021\/mp3005098","article-title":"Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis","volume":"10","author":"Duong","year":"2013","journal-title":"Mol Pharm."},{"key":"B113","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/jac\/dkt320","article-title":"Liposomal resiquimod for the treatment of leishmania donovani infection","volume":"69","author":"Peine","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"B114","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DDDT.S146521","article-title":"Leishmaniasis in humans: drug or vaccine therapy?","author":"Ghorbani","year":"2017","journal-title":"Drug Des Develop Therapy."},{"key":"B115","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijpvm.IJPVM_116_18","article-title":"Leishmania vaccines entered in clinical trials: a review of literature","volume":"10","author":"Moafi","year":"2019","journal-title":"Int J Prev Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bjid.2014.10.009","article-title":"Therapy with radio-attenuated vaccine in experimental murine visceral leishmaniasis showed enhanced T cell and inducible nitric oxide synthase levels, suppressed tumor growth factor-beta production with higher expression of some signaling molecules","volume":"19","author":"Datta","year":"2015","journal-title":"Brazilian J Infect Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1016\/S0264-410X(03)00527-9","volume":"21","author":"Santos","year":"2003","journal-title":"Vaccine."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune\u00ae) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine."},{"key":"B120","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/infdis\/jir842","article-title":"Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis","volume":"205","author":"Maroof","year":"2012","journal-title":"J Infect Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","volume":"422","author":"Jain","year":"2015","journal-title":"J Immunol Methods."},{"key":"B122","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.2147\/IJN.S141069","article-title":"Vaccination with poly (D, L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNF\u03b1-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis","volume":"12","author":"Margaroni","year":"2017","journal-title":"Int J Nanomedicine."},{"key":"B123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1021\/mp2002494","article-title":"Vaccination with liposomal leishmanial antigens adjuvanted with MPL-TDM confers long-term protection against visceral leishmaniasis through human adminstrable route","volume":"9","author":"Ravindran","year":"2012","journal-title":"Mol Pharm."},{"key":"B124","doi-asserted-by":"publisher","first-page":"8771","DOI":"10.1016\/j.vaccine.2007.10.028","article-title":"Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB\/c mice","volume":"25","author":"Mazumder","year":"2007","journal-title":"Vaccine."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111684","author":"Tosyali","year":"2020","journal-title":"Nano-Co-Delivery of Lipophosphoglycan With Soluble and Autoclaved Leishmania Antigens Into PLGA Nanoparticles: Evaluation of In Vitro and In Vivo"},{"key":"B126","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1586\/14760584.2014.894467","article-title":"Identifying vaccine targets for anti-leishmanial vaccine development","volume":"13","author":"Sundar","year":"2014","journal-title":"Expert Rev Vaccines."},{"key":"B127","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.vaccine.2011.11.005","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","volume":"30","author":"Duthie","year":"2012","journal-title":"Vaccine."},{"key":"B128","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/S0037-86821996000200008","article-title":"The FML (Fucose Mannose Ligand) of Leishmania donovani: a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar","volume":"29","author":"Sousa","year":"1996","journal-title":"Rev Soc Bras Med Trop."},{"key":"B129","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fimmu.2014.00380","article-title":"Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches","volume":"5","author":"Joshi","year":"2014","journal-title":"Front Immunol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"e00244","DOI":"10.1016\/j.parepi.2022.e00244","article-title":"Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria","volume":"16","author":"Gujjari","year":"2022","journal-title":"Parasite Epidemiol Control."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01677-2","article-title":"A split influenza vaccine formulated with a combination adjuvant composed of alpha-d-glucan nanoparticles and a STING agonist elicits cross-protective immunity in pigs","volume":"20","author":"Patil","year":"2022","journal-title":"J Nanobiotechnol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms8071069","article-title":"Can we harness immune responses to improve drug treatment in leishmaniasis?","volume":"8","author":"Aruleba","year":"2020","journal-title":"Microorganisms."},{"key":"B133","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1128\/IAI.71.11.6453-6462.2003","article-title":"Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis","volume":"71","author":"Murray","year":"2003","journal-title":"Infect Immun."},{"key":"B134","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/21505594.2022.2074130","article-title":"The pathogenicity and virulence of Leishmania-interplay of virulence factors with host defenses","volume":"13","author":"Gupta","year":"2022","journal-title":"Virulence."},{"key":"B135","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.actatropica.2004.11.008","article-title":"Interleukin 10 receptor blockade\u2014pentavalent antimony treatment in experimental visceral leishmaniasis","volume":"93","author":"Murray","year":"2005","journal-title":"Acta Trop."},{"key":"B136","doi-asserted-by":"publisher","first-page":"624009","DOI":"10.3389\/fcimb.2021.624009","article-title":"Role of cytokines in experimental and human visceral Leishmaniasis","volume":"11","author":"Samant","year":"2021","journal-title":"Front Cell Infect Microbiol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"100043","DOI":"10.1016\/j.cytox.2020.100043","article-title":"Unravelling the unsolved paradoxes of cytokine families in host resistance and susceptibility to leishmania infection","volume":"2","author":"Osero","year":"2020","journal-title":"Cytokine: X."},{"key":"B138","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ijbiomac.2022.02.006","article-title":"Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system","volume":"204","author":"Singh","year":"2022","journal-title":"Int J Biol Macromol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/immuno2010015","article-title":"Host\u2013pathogen interaction in leishmaniasis: immune response and vaccination strategies","volume":"2","author":"Yasmin","year":"2022","journal-title":"Immuno."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.1c00859","article-title":"Coalition of biological agent (Melatonin) with chemotherapeutic agent (Amphotericin b) for combating visceral leishmaniasis via oral administration of modified solid lipid nanoparticles","author":"Parvez","year":"2021","journal-title":"ACS Biomater Sci Eng."},{"key":"B141","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3347\/kjp.2022.60.6.379","article-title":"Leishmania vaccines: the current situation with its promising aspect for the future","volume":"60","author":"Dinc","year":"2022","journal-title":"Korean J Parasitol."},{"key":"B142","article-title":"Leishmaniasis in murine visceral \u03b2 the importance of TGF","author":"Mente","year":"2021"},{"key":"B143","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ced.14919","article-title":"Treatment options for leishmaniasis","volume":"47","author":"Pradhan","year":"2022","journal-title":"Clin Exp Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1096458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:14:47Z","timestamp":1684300487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1096458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":143,"alternative-id":["10.3389\/fmed.2023.1096458"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1096458","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"article-number":"1096458"}}